Gastrointestinal symptoms in low-dose aspirin users: A comparison between plain and buffered aspirin

Netherlands Heart Journal

Volumn 22, Issue 3, 2014, Pages 107-112

  Jaspers Focks, J ^a   Tielemans, M M ^a   van Rossum, L G M ^a   Eikendal, T ^a   Brouwer, M A ^a   Jansen, J B M J ^b   Laheij, R J F ^c   Verheugt, F W A ^a   van Oijen, M G H ^c,d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ELKERLIEK HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Community based population; Effervescent calcium carbasalate; Gastrointestinal symptoms; Low dose aspirin; Survey

Indexed keywords

ACETYLSALICYLIC ACID; CARBASALATE CALCIUM;

ADULT; ARTICLE; BLOATING; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONSTIPATION; DEFECATION URGENCY; DIARRHEA; DRUG INDUCED DISEASE; DYSPEPSIA; DYSPHAGIA; EFFERVESCENT TABLET; EPIGASTRIC PAIN; ERUCTATION; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; INFLAMMATORY BOWEL DISEASE; LIKERT SCALE; LOSS OF APPETITE; LOW DRUG DOSE; LOWER ABDOMINAL PAIN; MALE; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PAINFUL DEFECATION; PREVALENCE; QUESTIONNAIRE; SATIETY; STOMACH HEMORRHAGE; STOMACH ULCER; VOMITING;

EID: 84895430803     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-014-0522-3     Document Type: Article

References (31)

1. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373(6978):1849-60.
2. Lanas A, Wu P, Medin J, et al. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol. 2011;9(9):762-8.
3. Lanas A, McCarthy D, Voelker M, et al. Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. Drugs R D. 2011;11(3):277-88.
4. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22(9):795-801.
5. Niv Y, Battler A, Abuksis G, et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci. 2005;50(1):78-80.
6. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long-term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183-7.
7. Laheij RJ, Jansen JB, Verbeek AL, et al. Helicobacter Pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease. Aliment Pharmacol Ther. 2001;15(7):1055-9.
8. Pratt S, Thompson VJ, Elkin EP, et al. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs. 2010;10(5):281-8.
9. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomized, controlled trial (OBERON). Heart. 2011;97(10):797-802.
10. Cayla G, Collet JP, Silvain J, et al. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol. 2012;156(1):69-75.
11. De Groot NL, van Haalen HG, Spiegel BM, et al. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance. Cardiovasc Drugs Ther. 2013;27(4):341-57.
12. Aro P, Talley NJ, Agréus L, et al. Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther. 2011;33(11):1215-24.
13. Murray FE, Hudson N, Atherton JC, et al. Comparison of effects if calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Gut. 1996;38(1):11-4.
14. Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther. 1993;15(2):314-20.
15. Hoftiezer JW, Silvoso GR, Burks M, et al. Comparison of the regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet. 1980;2(8195):609-12.
16. Cryer B, Bhatt DL, Lanza FL, et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106(2):272-7.
17. Cole AT, Hudson N, Liew LC, et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Aliment Pharmacol Ther. 1999;13(2):187-93.
18. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther. 1999;13(8):1109-14.
19. Van Oijen MG, Dieleman JP, Laheij RJ, et al. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol. 2008;6(3):309-13.
20. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348(9039):1413-16.
21. De Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1.
22. Van Oijen MGH, Jaspers Focks J, Laheij RJF. Comparison of incident dyspepsia between low-dose plain aspirin and enteric-coated aspirin. Clin Gastroenterol Hepatol. 2010;8(4):395.
23. The Netherlands Foundation for Pharmaceutical Statistics/www.s2.nl; Facts and Figures of 2012; accessed on May 21st 2013.
24. Tielemans MM, Jaspers Focks J, van Rossum LGM, et al. Gastrointestinal symptoms are still prevalent and negatively impact health-related quality of life: a large cross-sectional population based study in the Netherlands. PLOS One. 2013;8(7): e69876.
25. Van Marrewijk CJ, Mujakovic S, Fransen GA, et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. Lancet. 2009;373(9659):215-25.
26. Bovenschen HJ, Janssen MJ, van Oijen MG, et al. Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis Sci. 2006;51(9): 1509-15.
27. Likert R. A technique for the measurement of attitudes. Arch Psychol. 1932;140:55.
28. College voor zorgverzekeringen/www.medicijnkosten.nl; accessed on July 25th 2013.
29. Yeomans ND, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103(10):2465-73.
30. Laheij RJ, van Rossum LG, Jansen JB, et al. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther. 2003;18(1):109-15.
31. Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ, et al. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. J Cardiovasc Pharmacol. 2013;61(3):250-7.